Regional Disparities in Adherence to Guidelines for the Treatment of Chronic Heart Failure.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
2021
Historique:
entrez: 15 2 2021
pubmed: 16 2 2021
medline: 15 4 2021
Statut: ppublish

Résumé

Objective The incidence of chronic heart failure (CHF) is likely to keep increasing in Japan as the population ages, placing increased burdens on medical facilities, particularly on the limited numbers of rural hospitals. We explored the appropriateness of CHF treatment in rural areas in Japan. Methods We compared rates of adherence to therapeutic guidelines for CHF between residents with a left ventricular ejection fraction <35% living in urban areas (n = 207) and those in rural areas (n = 180). Treatments included pharmacological [beta-blockers, angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blocker (ARB), mineralocorticoid receptor antagonist (MRA) and anticoagulants for atrial fibrillation] and non-pharmacological [implantable cardioverter defibrillator (ICD)/cardiac resynchronization therapy (CRT), cardiac rehabilitation and HF education] approaches. Patients This study included 387 patients with CHF, prior myocardial infarction or cardiomyopathy, and a left ventricular ejection fraction (LVEF) <35% as determined by echocardiography. Results The respective rates of treatments administered in urban and rural areas were as follows: beta-blockers, 91.3% vs. 61.7% (p<0.05); ACEi/ARB, 86.5% vs. 68.3% (p<0.05); MRA, 74.4% vs. 59.4% (p<0.01); anticoagulants, 100% vs. 86.5%, (p<0.05); ICD/CRT, 45.4% vs. 5.0% (p<0.05); cardiac rehabilitation, 32.4% vs. 13.3% (p<0.05) and HF education, 33.3% vs. 32.8% (p=0.75). Conclusion Regional disparities in treatment for CHF persist, even in Japan. Improvements in the use of guideline-directed treatment in rural areas might improve the outcomes for CHF patients.

Identifiants

pubmed: 33583932
doi: 10.2169/internalmedicine.4660-20
pmc: PMC7946489
doi:

Substances chimiques

Angiotensin Receptor Antagonists 0
Angiotensin-Converting Enzyme Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

525-532

Références

Intern Med. 2003 May;42(5):383-8
pubmed: 12793706
N Engl J Med. 1996 Dec 26;335(26):1933-40
pubmed: 8960472
BMJ Open. 2017 Mar 10;7(3):e013648
pubmed: 28283487
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
N Engl J Med. 1996 May 23;334(21):1349-55
pubmed: 8614419
J Am Coll Cardiol. 2018 Jan 30;71(4):386-398
pubmed: 29389354
Circ J. 2008 Mar;72(3):489-91
pubmed: 18296852
N Engl J Med. 2011 Apr 14;364(15):1395-406
pubmed: 21463154
N Engl J Med. 2005 Apr 14;352(15):1539-49
pubmed: 15753115
Am Heart J. 2010 Jun;159(6):949-955.e1
pubmed: 20569705
J Am Coll Cardiol. 1995 Dec;26(7):1565-74
pubmed: 7594087
Circ J. 2011;75(10):2403-10
pubmed: 21778592
Heart. 1997 May;77(5):423-7
pubmed: 9196411
N Engl J Med. 1987 Jun 4;316(23):1429-35
pubmed: 2883575
JACC Heart Fail. 2017 Nov;5(11):763-771
pubmed: 29032140
Am Heart J. 2007 Jul;154(1):12-38
pubmed: 17584548
Circulation. 2003 Dec 9;108(23):2883-91
pubmed: 14623812
JAMA. 2001 Jun 6;285(21):2743-9
pubmed: 11386930
N Engl J Med. 2005 Jan 20;352(3):225-37
pubmed: 15659722
Intern Med. 2019 Aug 1;58(15):2145-2150
pubmed: 31178494
N Engl J Med. 2002 Mar 21;346(12):877-83
pubmed: 11907286
N Engl J Med. 2001 May 31;344(22):1651-8
pubmed: 11386263
N Engl J Med. 2004 May 20;350(21):2140-50
pubmed: 15152059
Circulation. 2000 Aug 15;102(7):748-54
pubmed: 10942742
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
J Am Coll Cardiol. 2018 Jul 24;72(4):351-366
pubmed: 30025570
Lancet. 1999 Jan 2;353(9146):9-13
pubmed: 10023943
N Engl J Med. 2004 May 20;350(21):2151-8
pubmed: 15152060
Int J Cardiol Heart Vasc. 2020 Mar 20;27:100497
pubmed: 32215317
N Engl J Med. 1997 Nov 27;337(22):1576-83
pubmed: 9411221
Circulation. 2000 Mar 21;101(11):1297-302
pubmed: 10725290
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
Am Heart J. 2001 Oct;142(4):E7
pubmed: 11579371
Eur Heart J. 2000 Dec;21(24):2071-8
pubmed: 11102258
Lancet. 2014 Aug 16;384(9943):583-590
pubmed: 25131977
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811

Auteurs

Yuji Matsuo (Y)

Department of Internal Medicine, Niigata Prefectural Tokamachi Hospital, Japan.

Fumitoshi Yoshimine (F)

Department of Internal Medicine, Niigata Prefectural Tokamachi Hospital, Japan.

Katsuya Fuse (K)

Department of Internal Medicine, Uonuma City Koide Hospital, Japan.

Kazuo Suzuki (K)

Department of Internal Medicine, Niigata Prefectural Matsudai Hospital, Japan.

Takuya Sakamoto (T)

Department of Internal Medicine, Tsunan Town Hospital, Japan.

Kenichi Iijima (K)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan.

Kazuyuki Ozaki (K)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan.

Tohru Minamino (T)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH